Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer
Journal Title: OncoReview - Year 2015, Vol 5, Issue 2
Abstract
Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this way is less cardiotoxic. As a result of that, there is the possibility to use liposomal form of doxorubicin until disease progression or chemotherapy intolerance in palliative setting, without treatment cessation after reaching the maximum cumulative dose of conventional doxorubicin. In this article we describe the case of a female patient diagnosed with breast cancer who was primary treated with adjuvant treatment, including chemotherapy and in whom a disease recurrence occurred after seven years of observation. As a primary palliative treatment the patient received chemotherapy based on liposomal doxorubicin and cyclofosphamide with a very good tolerance. The initial response was partial remission in lungs and in mediastinal lymph nodes. During the whole course of therapy there were no pathological changes in electrocardiogram, no signs and no symptoms of congestive heart failure, and the left ventricular ejection fraction was within normal limits.
Authors and Affiliations
Joanna Streb, Agnieszka Słowik
Keywords
Related Articles
- EP ID EP67782
- DOI -
- Views 200
- Downloads 0
The mTOR signalling pathways in the pathogenesis and treatment of neuroendocrine tumours
Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasms.The majority of patients are diagnosed with locally advanced or metastatic disease, and curative surgery is rarely an option. Treatment approac...
Cardiovascular concerns from radiation therapy and other radiation exposure
Rehabilitation of patients with cancer of the respiratory system
Many patients with lung cancer have concomitant chronic obstructive pulmonary disease and heart diseases. The planned anticancer therapy should be individualized in relationship of patient’s cardiac and pulmonary conditi...
Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells
Treatment of myeloma has changed significantly in the past decade as results of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT)...
Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin
Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disea...